Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
InnoCan Pharma: Jetzt in die Doppel-Chance investieren?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D9Z3 | ISIN: US30048L3024 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
EVOFEM BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
EVOFEM BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur EVOFEM BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Evofem Biosciences GAAP EPS of -$0.16, revenue of $3.6M4
15.05.Evofem Biosciences, Inc. - 8-K, Current Report1
15.05.Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the First Quarter of 2024110SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the...
► Artikel lesen
15.05.Evofem Biosciences, Inc. - 10-Q, Quarterly Report1
02.05.Evofem Biosciences, Inc. - 8-K, Current Report6
27.03.Evofem Biosciences, Inc. - 10-K, Annual Report7
27.03.Evofem Biosciences, Inc. - 8-K, Current Report3
27.03.Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023300-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth...
► Artikel lesen
20.03.Evofem Biosciences, Inc.: Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal117- Medi-Cal serves more than 15.4 million Californians - - 7.4% improvement in Phexxi rebate to take effect July 1, 2024 - SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's health...
► Artikel lesen
06.03.Evofem Biosciences, Inc. - 8-K, Current Report8
01.02.Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M11
01.02.Evofem Biosciences, Inc.: Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023369Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc....
► Artikel lesen
31.01.Evofem Biosciences, Inc. - 8-K, Current Report4
11.01.Evofem Biosciences, Inc. - 8-K, Current Report8
13.12.23Aditxt acquires Phexxi contraceptive gel-maker Evofem for $100m15
12.12.23Why Is Evofem (EVFM) Stock Up 85% Today?15
12.12.23Troubled Evofem, marketer of contraceptive gel Phexxi, sells itself to Aditxt in $100M deal6
12.12.23Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally280RICHMOND, Va. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations,...
► Artikel lesen
07.12.23Evofem Biosciences, Inc. - 8-K, Current Report5
14.11.23Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 20231.243- On track to achieve third consecutive year of revenue growth - - Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales - - Reduced loss from operations by...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1